Bayer stock heads into the open after a 1.3% Xetra decline
Published on 09/16/2026 at 08:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bayer stock closed at EUR 48.71 on Xetra on September 15, 2026, representing a 1.26% decline versus the prior session in Frankfurt. Compared with the DAX, which ended the same day virtually unchanged around 25,415.84 points, Bayer stock underperformed the broader German market.
September 15, 2026 in numbers
Bayer AG (ISIN DE000BAY0017) ended Xetra trading on September 15, 2026 at EUR 48.71, with official closing data from Deutsche Boerse showing a session loss of 1.26% and volume of about 2,000,716 shares. According to quote overviews that summarize the Xetra order book, the stock traded during the session between roughly EUR 48.41 at the low and EUR 49.49 at the high, placing the close nearer to the bottom of the intraday range and still well above the 52-week low of EUR 25.78 cited in recent market data summaries. Per data compiled by German market commentators, this pullback followed a gain of roughly 2.4% in the prior Xetra session, when Bayer had closed around EUR 49.33, so the stock surrendered part of those earlier advances while the DAX itself finished September 15, 2026 almost flat at 25,415.84 points.
Today’s outlook for Bayer stock
Today, Bayer stock approaches the Frankfurt open without a newly announced company event explicitly scheduled for September 16, 2026 in the latest public calendars, so trading interest is likely to remain sensitive to broader moves in German equities and pharmaceuticals. Recent coverage from German financial media highlighted that Bayer shares were among the stronger DAX constituents earlier this week, which may keep attention on any follow-up sector news or regulatory developments that could affect sentiment toward large pharma names. In the near term, investors also continue to monitor ongoing legal and settlement discussions around legacy herbicide litigation as reported by European market wraps, because changes in perceived litigation risk can quickly translate into shifts in Bayer’s share price even in the absence of fresh earnings disclosures.
